title: Breast Ductal CarcinomaIn Situ: A Literature Review of Adjuvant Hormonal Therapy.
abstract: This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinomain situ(DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Metaanalysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.
authors.affiliation: Modbury Hospital , Modbury, Australia.
authors.forename: Stephen
authors.initials: S
authors.lastname: Kinsey-Trotman
authors.affiliation: The University of Adelaide , Adelaide, Australia.
authors.forename: Zumin
authors.initials: Z
authors.lastname: Shi
authors.affiliation: Modbury Hospital , Modbury, Australia.
authors.forename: Beverley
authors.initials: B
authors.lastname: Fosh
keywords: Ductal carcinoma in situ; adjuvant; aromatase inhibitor; breast cancer; hormonal; tamoxifen